Millrace Asset Group Lowers stake in Enzo Biochem (ENZ)

Enzo Biochem (ENZ) : Millrace Asset Group reduced its stake in Enzo Biochem by 19.25% during the most recent quarter end. The investment management company now holds a total of 425,762 shares of Enzo Biochem which is valued at $2.6 Million after selling 101,512 shares in Enzo Biochem , the firm said in a disclosure report filed with the SEC on May 13, 2016.Enzo Biochem makes up approximately 3.80% of Millrace Asset Group’s portfolio.

Other Hedge Funds, Including , Renaissance Technologies boosted its stake in ENZ in the latest quarter, The investment management firm added 196,800 additional shares and now holds a total of 1,449,900 shares of Enzo Biochem which is valued at $8.8 Million. Enzo Biochem makes up approx 0.02% of Renaissance Technologies’s portfolio.Ubs Asset Management Americas Inc reduced its stake in ENZ by selling 126,524 shares or 18.99% in the most recent quarter. The Hedge Fund company now holds 539,867 shares of ENZ which is valued at $3.3 Million.Blackrock Fund Advisors reduced its stake in ENZ by selling 6,574 shares or 6.93% in the most recent quarter. The Hedge Fund company now holds 88,301 shares of ENZ which is valued at $534,221.Nine Chapters Capital Management reduced its stake in ENZ by selling 51,900 shares or 53.95% in the most recent quarter. The Hedge Fund company now holds 44,300 shares of ENZ which is valued at $268,015. Enzo Biochem makes up approx 0.02% of Nine Chapters Capital Management’s portfolio.

Enzo Biochem closed down -0.14 points or -2.21% at $6.2 with 1,45,612 shares getting traded on Wednesday. Post opening the session at $6.25, the shares hit an intraday low of $6.16 and an intraday high of $6.45 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

Enzo Biochem Inc. (Enzo) is an integrated life science and biotechnology company which is engaged in the research development manufacturing and marketing of diagnostic and research products based on genetic engineering biotechnology and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases cancers genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally. The Company operates through three segments: Enzo Life Sciences Enzo Clinical Labs and Enzo Therapeutics. Enzo Life Sciences segment manufactures develops and markets products and tools to clinical research drug development and bioscience research customers around the world. Enzo Clinical Labs segment provides diagnostic services to the healthcare community. Enzo Therapeutics segment conducts research and development activities for therapeutic drug candidates.

Leave a Reply

Enzo Biochem - Is it time to Sell?

Top Brokerage Firms are advising their investors on Enzo Biochem. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.